Skip to main content
. Author manuscript; available in PMC: 2023 Apr 18.
Published in final edited form as: Cell Rep. 2023 Mar 6;42(3):112203. doi: 10.1016/j.celrep.2023.112203

Figure 3. 2-Br-LSD has a safer cardiovascular profile compared to LSD.

Figure 3.

2-Br-LSD agonist and antagonist activity at 5-HT2B measuring Gq dissociation (A) and β-arrestin2 recruitment (B) in BRET assays, and in Gq-mediated calcium flux assays (C). Data represent mean and SEM from at least n=3 independent experiments performed in triplicate. Antagonist activity KB was calculated using, IC50, 5-HT competing concentration and EC50. (D) hERG inhibition by 2-Br-LSD (blue) indicating IC50 (half maximal inhibition) of 31.6 μM. Positive control astemizole (red) IC50 = 0.41 μM. Related to Tables S5, S6.